ÜBER DIESEN PODCAST 🔗

Durchschnittliche Audiolänge:
7 minutes
Englisch
Vereinigte Staaten
29 Folgen
seit 6. August 2015
episodic

NEUESTE FOLGEN 🔗

Prof Anton Hagenbeek (Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about immunoconjugates, the latest targeted treatments in Hodgkin's lymphoma. He also suggests that patients with Hodgkin's disease partake in clinical trials. ecan…

VERGANGENE FOLGEN SUCHEN

Vorhandene Folgen von EHA 2015 durchsuchen.

FRÜHERE EPISODEN

Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants. The researchers …
At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with …
Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
Dr Meletios Dimopoulos (National and Kapodistrian University of Athens, Athens, Greece) talks to ecancertv at EHA 2015 about the results of ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone and is the first Phase III study to demonstrate the benefit of direct…
Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.
Prof Anton Hagenbeek (University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about the results of Dr Andrew Roberts' early phase Ib trial which looked at combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL). ecanc…
Prof Diehl ( Winner of the Jean Bernard Lifetime Achievement Award) talks to ecancertv at EHA 2015 about his amazing work in the field of Hodgkin's lymphoma and the evolution of research and treatment strategies over time. ecancer's filming at EHA has been kindly supported by Amgen through the ECM…
Prof Max Topp ( Würzburg University Hospital, Würzburg, Germany) talks to ecancertv at EHA 2015 about his research which showed that acute lymphoblastic leukaemia (ALL) patients with low disease burden had lower responses to blinatumomab. Those with higher disease burden could be candidates for hig…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von ecancer, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.